Skip to main content
PMC home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1985 Apr 20;290(6476):1176–1178. doi: 10.1136/bmj.290.6476.1176

Prevalence of antibody to human T lymphotropic virus type III by risk group and area, United Kingdom 1978-84.

P P Mortimer, W J Jesson, E M Vandervelde, M S Pereira
PMCID: PMC1418883  PMID: 2985170

Abstract

Antibody to human T lymphotropic virus type III (anti-HTLV-III) was sought in 2150 patients in three groups at risk with a radioimmunoassay and an immunofluorescence test. Results by the two methods were closely concordant. Anti-HTLV-III was already present in some British homosexuals in 1980 and in some British haemophiliacs in 1981, and since then its prevalence has increased. Of homosexual patients needing laboratory tests for hepatitis B virus infection in 1984, 34% of 282 in London and 5% of 955 in five centres outside London were positive for anti-HTLV-III. Of haemophiliacs sampled in 1984, 38% of 81 were anti-HTLV-III positive. Most of the seropositive haemophiliacs were regular recipients of commercial factor VIII concentrates. Few British intravenous drug abusers sampled in 1984 (2.5% of 203) were positive for anti-HTLV-III. These results show that infection with HTLV-III has rapidly become widespread among homosexuals attending sexually transmitted disease clinics and among haemophiliacs receiving pooled blood products. Thus, while many anti-HTLV-III positive individuals may remain asymptomatic, there may soon be a considerable increase in the incidence of the acquired immune deficiency syndrome and related disease in Britain.

Full text

PDF
1176

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barré-Sinoussi F., Chermann J. C., Rey F., Nugeyre M. T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vézinet-Brun F., Rouzioux C. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983 May 20;220(4599):868–871. doi: 10.1126/science.6189183. [DOI] [PubMed] [Google Scholar]
  2. Brun-Vézinet F., Rouzioux C., Montagnier L., Chamaret S., Gruest J., Barré-Sinoussi F., Geroldi D., Chermann J. C., McCormick J., Mitchell S. Prevalence of antibodies to lymphadenopathy-associated retrovirus in African patients with AIDS. Science. 1984 Oct 26;226(4673):453–456. doi: 10.1126/science.6238406. [DOI] [PubMed] [Google Scholar]
  3. Cheingsong-Popov R., Weiss R. A., Dalgleish A., Tedder R. S., Shanson D. C., Jeffries D. J., Ferns R. B., Briggs E. M., Weller I. V., Mitton S. Prevalence of antibody to human T-lymphotropic virus type III in AIDS and AIDS-risk patients in Britain. Lancet. 1984 Sep 1;2(8401):477–480. doi: 10.1016/s0140-6736(84)92562-5. [DOI] [PubMed] [Google Scholar]
  4. Cohen B. J., Litton P. A., Mortimer P. P., Simmons P. Hepatitis B core antigen synthesised in Escherichia coli: its use for antibody screening in patients attending a clinic for sexually transmitted diseases. J Hyg (Lond) 1984 Oct;93(2):225–232. doi: 10.1017/s0022172400064743. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flehmig B., Zahn J., Vallbracht A. Levels of neutralizing and binding antibodies to hepatitis-A virus after onset of icterus: a comparison. J Infect Dis. 1984 Sep;150(3):461–461. doi: 10.1093/infdis/150.3.461. [DOI] [PubMed] [Google Scholar]
  6. Gallo R. C., Salahuddin S. Z., Popovic M., Shearer G. M., Kaplan M., Haynes B. F., Palker T. J., Redfield R., Oleske J., Safai B. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. Science. 1984 May 4;224(4648):500–503. doi: 10.1126/science.6200936. [DOI] [PubMed] [Google Scholar]
  7. Goldsmith M. F. HTLV-III testing of donor blood imminent; complex issues remain. JAMA. 1985 Jan 11;253(2):173-5, 179-81. doi: 10.1001/jama.253.2.173. [DOI] [PubMed] [Google Scholar]
  8. Groopman J. E., Salahuddin S. Z., Sarngadharan M. G., Markham P. D., Gonda M., Sliski A., Gallo R. C. HTLV-III in saliva of people with AIDS-related complex and healthy homosexual men at risk for AIDS. Science. 1984 Oct 26;226(4673):447–449. doi: 10.1126/science.6093247. [DOI] [PubMed] [Google Scholar]
  9. Hirsch M. S., Wormser G. P., Schooley R. T., Ho D. D., Felsenstein D., Hopkins C. C., Joline C., Duncanson F., Sarngadharan M. G., Saxinger C. Risk of nosocomial infection with human T-cell lymphotropic virus III (HTLV-III). N Engl J Med. 1985 Jan 3;312(1):1–4. doi: 10.1056/NEJM198501033120101. [DOI] [PubMed] [Google Scholar]
  10. Klatzmann D., Barré-Sinoussi F., Nugeyre M. T., Danquet C., Vilmer E., Griscelli C., Brun-Veziret F., Rouzioux C., Gluckman J. C., Chermann J. C. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984 Jul 6;225(4657):59–63. doi: 10.1126/science.6328660. [DOI] [PubMed] [Google Scholar]
  11. Lim K. S., Wong V. T., Fulford K. W., Catterall R. D., Briggs M., Dane D. S. Role of sexual and non-sexual practices in the transmission of hepatitis B. Br J Vener Dis. 1977 Jun;53(3):190–192. doi: 10.1136/sti.53.3.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Safai B., Sarngadharan M. G., Groopman J. E., Arnett K., Popovic M., Sliski A., Schüpbach J., Gallo R. C. Seroepidemiological studies of human T-lymphotropic retrovirus type III in acquired immunodeficiency syndrome. Lancet. 1984 Jun 30;1(8392):1438–1440. doi: 10.1016/s0140-6736(84)91933-0. [DOI] [PubMed] [Google Scholar]
  13. Shattock A. G., Kelly M. G., Fielding J., Arthurs Y. Epidemic hepatitis B with delta-antigenaemia among Dublin drug-abusers. Ir J Med Sci. 1982 Nov;151(11):334–338. doi: 10.1007/BF02940218. [DOI] [PubMed] [Google Scholar]
  14. Tedder R. S., Mortimer P. P., Lord R. B. Detection of antibody to varicella-zoster virus by competitive and IgM-antibody capture immunoassay. J Med Virol. 1981;8(2):89–101. doi: 10.1002/jmv.1890080203. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES